Anti-RMDN2 monoclonal antibody

Pre-made anti-RMDN2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to RMDN2/RMDN2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1497-Ab-1/ GM-Tg-hg-IP1497-Ab-2Anti-Human RMDN2 monoclonal antibodyHuman
GM-Tg-rg-IP1497-Ab-1/ GM-Tg-rg-IP1497-Ab-2Anti-Rat RMDN2 monoclonal antibodyRat
GM-Tg-mg-IP1497-Ab-1/ GM-Tg-mg-IP1497-Ab-2Anti-Mouse RMDN2 monoclonal antibodyMouse
GM-Tg-cynog-IP1497-Ab-1/ GM-Tg-cynog-IP1497-Ab-2Anti-Cynomolgus/ Rhesus macaque RMDN2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1497-Ab-1/ GM-Tg-felg-IP1497-Ab-2Anti-Feline RMDN2 monoclonal antibodyFeline
GM-Tg-cang-IP1497-Ab-1/ GM-Tg-cang-IP1497-Ab-2Anti-Canine RMDN2 monoclonal antibodyCanine
GM-Tg-bovg-IP1497-Ab-1/ GM-Tg-bovg-IP1497-Ab-2Anti-Bovine RMDN2 monoclonal antibodyBovine
GM-Tg-equg-IP1497-Ab-1/ GM-Tg-equg-IP1497-Ab-2Anti-Equine RMDN2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1497-Ab-1/ GM-Tg-hg-IP1497-Ab-2; GM-Tg-rg-IP1497-Ab-1/ GM-Tg-rg-IP1497-Ab-2;
GM-Tg-mg-IP1497-Ab-1/ GM-Tg-mg-IP1497-Ab-2; GM-Tg-cynog-IP1497-Ab-1/ GM-Tg-cynog-IP1497-Ab-2;
GM-Tg-felg-IP1497-Ab-1/ GM-Tg-felg-IP1497-Ab-2; GM-Tg-cang-IP1497-Ab-1/ GM-Tg-cang-IP1497-Ab-2;
GM-Tg-bovg-IP1497-Ab-1/ GM-Tg-bovg-IP1497-Ab-2; GM-Tg-equg-IP1497-Ab-1/ GM-Tg-equg-IP1497-Ab-2
Products NameAnti-RMDN2 monoclonal antibody
Formatmab
Target NameRMDN2
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-RMDN2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1497-Ag-1Recombinant multi-species RMD2/ RMDN2/ BLOCK18 protein


    Target information

    Target IDGM-IP1497
    Target NameRMDN2
    Gene ID151393,381110,313840,710209,483037,101100123,506362,100070111
    Gene Symbol and SynonymsBLOCK18,FAM82A,FAM82A1,mRMD-2,PRO34163,PYST9371,RMD-2,RMD2,RMD4,RMDN2
    Uniprot AccessionQ96LZ7,Q498D5,Q2TBQ7
    Uniprot Entry NameRMD2_HUMAN,RMD2_RAT,RMD2_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000115841
    Target ClassificationN/A

    The target: RMDN2, gene name: RMDN2, also named as BLOCK18, FAM82A, FAM82A1, PRO34163, PYST9371, RMD-2, RMD2, RMD4. Enables microtubule binding activity. Located in Golgi apparatus; cytosol; and spindle. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.